Biotech News
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results
ir.reparerx.com2026-05-06 15:28 EST
Exploring strategic alternatives to advance clinical stage pipeline and maximize shareholder value $124.2 million in cash and cash equivalents and marketable securities provides runway as of March 31, 2025 CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--May 13, 2025-- Repare Therapeutics Inc.